The fall was triggered after the Phase II trial changed its status to terminated. Credits: Medtech THAI STUDIO LAB 249/ Shutterstock.com.

The likelihood of approval (LoA) for Pfizer’s binimetinib in acute myeloid leukaemia (AML) plummeted 17 points on 21 April, according to GlobalData’s LoA data. The fall was triggered after the Phase II trial changed its status to terminated, on 20 April.

Previously, binimetinib had an LoA of 28% but this has now dropped to 11% following GlobalData’s LoA analysis, which uses a combination of machine learning and its proprietary algorithm, recalculated the score. According to results published in December 2020, binimetinib had minimal response for MAP-ERK kinase (MEK) inhibition in AML, along with a tolerable safety profile. The study, sponsored by M.D. Anderson Cancer Centre, has changed its status to terminated because of slow accrual, according to ClinicalTrials.gov.

Pfizer acquired Array in July 2019, with the expansion of binimetinib as a rationale for the acquisition, analyst reports at the time showed. On 30 March 2020, this news service reported that binimetinib, which is also being investigated within a triplet in Phase II ANCHOR trial in colorectal cancer (CRC), is unlikely to progress to a later Phase III because it is not increasing efficacy over the doublet and brings an additional side- effect burden.

Sean Rai-Roche is a Healthcare Reporter for Clinical Trials Arena parent company GlobalData’s investigative journalism team. A version of this article originally appeared on the Insights module of GlobalData’s Pharmaceutical Intelligence Center. To access more articles like this, visit GlobalData.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

Tick here to opt out of curated industry news, reports, and event updates from Clinical Trials Arena.

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.